Jaden's questions to 10X Genomics Inc (TXG) leadership • Q2 2025
Question
Jaden asked for the company's instrument placement assumptions for Visium, Xenium, and Chromium for the upcoming quarter and full year, as well as the key drivers for each platform.
Answer
CFO Adam Taich did not provide a specific breakdown of placements but indicated that Q3 instrument sales are expected to be 'fairly similar to Q2.' He noted that while there is typically a seasonal Q4 uplift in CapEx, visibility remains low in the current challenged environment. He affirmed the sales team is competing aggressively for every placement.